Semaglutide Bests Exenatide in Type 2 Diabetes Semaglutide Bests Exenatide in Type 2 Diabetes
Subcutaneous injection of semaglutide provides superior results to exenatide extended release (ER), also administered subcutaneously, in patients who have diabetes inadequately controlled by oral agents, according to findings from an open-label trial.Reuters Health Information (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 12, 2018 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news

BYDUREON(R) BCise(TM) Injectable Medicine Now Available In The US For Patients With Type-2 Diabetes
WILMINGTON, Del., Jan. 10, 2018 -- (Healthcare Sales & Marketing Network) -- AstraZeneca today announced that BYDUREON® BCise™ (exenatide extended-release) injectable suspension 2mg is now available in pharmacies across the United States. BYDUREON BCi... Biopharmaceuticals, Endocrinology, Product Launch AstraZeneca, BYDUREON BCise, exenatide (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - January 10, 2018 Category: Pharmaceuticals Source Type: news

Bydureon Bcise (Exenatide Extended-Release Injectable Suspension) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - December 18, 2017 Category: Drugs & Pharmacology Source Type: news

Bydureon Bcise (Exenatide Extended-Release Injectable Suspension) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - December 14, 2017 Category: Drugs & Pharmacology Source Type: news

Targeting a microRNA shows potential to enhance effectiveness of diabetes drugs
(University of Alabama at Birmingham) Researchers have found a vital role for miR-204 in beta cells -- regulating the cell surface receptor that is the target of many of the newer type 2 diabetes drugs, such as Byetta, Victoza, Trulicity, Januvia, Onglyza and Tradjenta. This drug target is the glucagon-like peptide 1 receptor, or GLP1R. Activation of GLP1R with these drugs helps the beta cell produce and secrete more insulin. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 7, 2017 Category: International Medicine & Public Health Source Type: news

FDA clears AstraZeneca ’s once-weekly Type II diabetes drug-device combo
AstraZeneca (NYSE:AZN) said today that the FDA approved its once-weekly exenatide drug in a single-dose auto-injector for adults with Type II diabetes whose blood sugar is uncontrolled on one or more oral drugs. The company’s drug, Bydureon, is formulated with a continuous-release microsphere delivery system designed to provide consistent levels of exenatide, according to AstraZeneca, to reduce blood sugar levels in people with diabetes. Get the full story at our sister site, Drug Delivery Business News. The post FDA clears AstraZeneca’s once-weekly Type II diabetes drug-device combo appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - October 23, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Diabetes Drug-Device Combinations Food & Drug Administration (FDA) Pharmaceuticals Regulatory/Compliance Wall Street Beat AstraZeneca plc Source Type: news

FDA Approves Once-Weekly Bydureon BCise (exenatide) for Patients with Type-2 Diabetes
23 October 2017 -- AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved Bydureon ® BCise™ (exenatide extended-release) injectable suspension, a new formulation of Bydureon (exenatide extended-release) injectable... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - October 23, 2017 Category: Drugs & Pharmacology Source Type: news

FDA deals setback to Intarcia for diabetes implant
Privately-held biopharma Intarcia Therapeutics revealed today that the FDA rejected its exenatide implant, ITCA 650, designed to treat Type II diabetes. The company said that it doesn’t think it will need to conduct new pivotal trials in order to address the concerns brought about by the FDA’s complete response letter. Get the full story at our sister site, Drug Delivery Business News. The post FDA deals setback to Intarcia for diabetes implant appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - September 28, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Diabetes Drug-Device Combinations Food & Drug Administration (FDA) Implants Pharmaceuticals Regulatory/Compliance Intarcia Therapeutics Source Type: news

GLP-1 diabetes drug neutral for the heart
Extended-release exenatide (Bydureon) is safe for the heart but does not help prevent cardiovascular events in type 2 diabetes, a study published in theNew England Journal of Medicinereports.MedPage Today (Source: Society for Endocrinology)
Source: Society for Endocrinology - September 15, 2017 Category: Endocrinology Source Type: news

In Type 2 Diabetes, Adding Once-Weekly Exenatide Doesn't Improve CV Outcomes (FREE)
By Amy Orciari Herman Edited by Andr é Sofair, MD, MPH, and William E. Chavey, MD, MS Adding the injectable type 2 diabetes drug exenatide (Byetta) to usual care does not improve cardiovascular outcomes, according to an … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - September 14, 2017 Category: Primary Care Source Type: news

GLP-1 Diabetes Drug Neutral for the Heart (CME/CE)
(MedPage Today) -- Once-weekly exenatide safe for CV outcomes but falls short of showing benefit (Source: MedPage Today Endocrinology)
Source: MedPage Today Endocrinology - September 14, 2017 Category: Endocrinology Source Type: news

EXSCEL:'Disappointment' Spurs Discussion on GLP-1 Agonists in Diabetes EXSCEL:'Disappointment' Spurs Discussion on GLP-1 Agonists in Diabetes
Full details of EXSCEL with the GLP-1 agonist exenatide, in which the agent didn ' t show any cardiovascular benefit over placebo in type 2 diabetes, provide"some good news" but also"some disappointment."Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - September 14, 2017 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news

A1c, Weight Loss Benefit Seen With Exenatide-Glargine Combo
(MedPage Today) -- No increased risk for hypoglycemia reported (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - September 12, 2017 Category: Cardiology Source Type: news

More people treated with once-weekly semaglutide achieved reductions in both glucose and weight vs. comparator treatments
A post-hoc analysis of the SUSTAIN 1-5 trials demonstrated that a greater proportion of adults with type 2 diabetes achieved a clinically meaningful reduction in both HbA1c and body weight with once-weekly semaglutide vs. comparator treatments. Comparators included placebo, sitagliptin, insulin glargine U100 or exenatide extended release (ER). (Source: World Pharma News)
Source: World Pharma News - September 12, 2017 Category: Pharmaceuticals Tags: Featured Novo Nordisk Business and Industry Source Type: news

Scientists Discover Existing Diabetes Drug Reduces Sight-threatening...
Research led by the University of Birmingham, UK, published in Science Translational Medicine, shows that a GLP-1 receptor agonist drug, Exenatide, treats raised brain pressure in animal models.(PRWeb September 07, 2017)Read the full story at http://www.prweb.com/releases/2017/09/prweb14659458.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - September 7, 2017 Category: Pharmaceuticals Source Type: news